Non-small cell lung cancer
Conditions
Interventions
Maintenance TS-1
Sponsors
National Cancer Center Research Hospital East
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) pathologically diagnosed non-small cell lung cancer patients 2) clinically stage IV (UICC, 7th edition) 3) CR, PR, or SD was achieved after prior platinum-doublet chemotherapy 4) No history of chemotherapy other than lung cancer, and radiotherapy of primary lung lesion 5) ECOG PS 0-1 6) Good major organ function 7) Written informed consent by patient
Exclusion criteria
Exclusion criteria: 1) active multiple malignancy 2) infection, ileus, vomiting 3) history of hemoptysis 4) history of thrombotic or hemorrhagic disorders 5) tumor invasion to major thoracic vessel 6) tumor cavitation 7) nonhealing bone fracture 8) uncontrolled digestive ulcer 9) uncontrolled hypertension 10) interstitial pneumonia 11) pregnancy or lactation 12) symptomatic brain metastasis 13) severe drug allergy 3)-6) was excluded only in patients who received bevacizumab-containing first-line chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to treatment failure | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of adverse events, progression-free survival, overall survival | — |
Countries
Japan
Contacts
Public ContactSeiji Niho
National Cancer Research Center Hospital East Division of thoracic oncology
Outcome results
None listed